Playground →
The top 10 nearest neighbors to AstraZeneca split cleanly into two subcategory groups — Healthcare brands and B2B services — with no single neighbor pulling far ahead of the rest.
The shape is flat: scores run from 0.98 at the top down to 0.94 at position 10, a band of less than four percentage points across the entire set. Novartis leads at 0.98, followed closely by GSK at 0.98 and Amgen at 0.97 — all Healthcare brands. Then the set shifts: Accenture at 0.96, IBM Data and AI at 0.95, and IBM at 0.95 are B2B services firms, not healthcare companies. Deloitte at 0.95 continues that B2B thread before the list returns to Healthcare with Pfizer Inc. at 0.94, Johnson & Johnson at 0.94, and Bristol Myers Squibb at 0.94. The final tally: six Healthcare brands and four B2B services brands across the top 10, with no Technology, Media, or consumer-facing subcategory appearing at all. The cross-kind presence of major consulting and enterprise IT firms alongside direct pharma peers is the defining structural feature — this audience follows the professional and institutional layer of both industries simultaneously.
The flat, tightly compressed scores across a Healthcare-and-B2B mix point to an audience shaped by institutional professional interest rather than any single sector loyalty.
